Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | GRK5 | P34947 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PRKX | P51817 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617515 | 0.84 | MAPT (0.37) | KDM4EALDH1A1POLBCHEK1ABL1 | |
| SCHEMBL13082119 | 0.82 | KDM5A (0.32) | KDM4EALDH1A1POLBJAK3CHEK1 | |
| SCHEMBL30826009 | 0.78 | ALDH1A1 (0.40) | KDM4EALDH1A1POLBCHEK1ABL1 | |
| SCHEMBL15142766 | 0.78 | PIK3CD (0.40) | KDM4EALDH1A1POLBCLK4PIK3CD | |
| SCHEMBL8896520 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1POLBCLK4PIK3CD | |
| SCHEMBL23509034 | 0.78 | HPGD (0.33) | KDM4EALDH1A1POLBJAK3CHEK1 | |
| SCHEMBL8139272 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1POLBJAK3CLK4 | |
| SCHEMBL2614511 | 0.78 | CYP11B1 (0.35) | KDM4EALDH1A1POLBJAK3CHEK1 | |
| SCHEMBL14932502 | 0.78 | PIK3CD (0.33) | KDM4EALDH1A1POLBCHEK1ABL1 | |
| SCHEMBL18296394 | 0.78 | ALDH1A1 (0.40) | KDM4EALDH1A1POLBCHEK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11647671-B2 | Compound and organic electro-optical device containing the same | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-20230012570-A1 | BICYCLIC COMPOUND USED AS SELECTIVE ANDROGEN RECEPTOR MODULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-23 | — | — | US | disclosed |
| US-9221828-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides as pharmaceuticals | SANOFI (FR) | 2015-12-29 | — | — | US | disclosed |
| US-9174993-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2015-11-03 | — | — | US | disclosed |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-0680955-B1 | PROCESS FOR PRODUCING N-tert-BUTYL-2-PYRAZINECARBOXAMIDE AND N-tert-BUTYL-2-PIPERAZINECARBOXAMIDE | KOEI CHEMICAL CO (JP) | 2002-09-18 | — | — | EP | disclosed |
| US-5922873-A | Process for preparing N-tert-butyl-2-pyrazinecarboxamide and N-tert-butyl-2-piperazinecarboxamide | KOEI CHEMICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5734055-A | Process for preparing N-tert-butyl-2-pyrazinecarboxamide and N-tert-butyl-2-piperazinecarboxamide | KOEI CHEMICAL CO. LTD. (JP) | 1998-03-31 | — | — | US | disclosed |
| EP-0680955-A1 | PROCESS FOR PRODUCING N-tert-BUTYL-2-PYRAZINECARBOXAMIDE AND N-tert-BUTYL-2-PIPERAZINECARBOXAMIDE | KOEI CHEMICAL CO., LTD. (JP) | 1995-11-08 | — | — | EP | disclosed |
| EP-0111160-B1 | PROCESS FOR THE PREPARATION OF 2-HALOGEN AND 2-CYANO PYRAZINES | BASF Aktiengesellschaft (DE) | 1986-10-22 | — | — | EP | disclosed |
| EP-0111160-A1 | Process for the preparation of 2-halogen and 2-cyano pyrazines | BASF Aktiengesellschaft (DE) | 1984-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | KDM4E 2910/4885ALDH1A1 2371/4885POLB 4551/4885 |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | KDM4E 657/4885ALDH1A1 1767/4885POLB 3362/4885 |
| US-11647671-B2 | Compound and organic electro-optical device containing the same | EPCAM, LPO, CYBA | KDM4E 507/4885ALDH1A1 1369/4885POLB 1647/4885 |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | KDM4E 2910/4885ALDH1A1 2371/4885POLB 4551/4885 |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK3, SGK1, SGK2 | KDM4E 3378/4885ALDH1A1 2508/4885POLB 4508/4885 |
| US-20230012570-A1 | BICYCLIC COMPOUND USED AS SELECTIVE ANDROGEN RECEPTOR MODULATOR | AR, NR5A1, CYP17A1 | KDM4E 1483/4885ALDH1A1 936/4885POLB 4200/4885 |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | KDM4E 2910/4885ALDH1A1 2371/4885POLB 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.